During ECP treatment, CTCL patients are characterized by an early decrease of CD4+CD25+bright (from 4.3 percent to 2.4 percent median after 6 months). This evidence concerns the gene CD4 and primary cutaneous T-cell non-Hodgkin lymphoma.